

# COPY FOR PTO

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The following documents have been received:

Reponse to the August 25, 2003 Notice to Comply (3 pages); Copy of Notice to Comply (1 page); Sequence Listing (3 pages); Diskette Containing Sequence Listing; Statement Under 37 C.F.R. 1.821(f) and (g); NO FEE

**Applicant :** Teresa Compton, et al.  
**Serial No. :** 09/942,146  
**Patent No. :** N/A  
**Title:** HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN O AS A NEW DRUG TARGET AND SUBUNIT VACCINE CANDIDATE  
**Date:** 9/4/2003  
**Our File:** 960296.98342  
**Attorney:** ZREN  
**Secretary:** arolph

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


The following documents have been received:

Reponse to the August 25, 2003 Notice to Comply (3 pages); Copy of Notice to Comply (1 page); Sequence Listing (3 pages); Diskette Containing Sequence Listing; Statement Under 37 C.F.R. 1.821(f) and (g); NO FEE

**Applicant :** Teresa Compton, et al.  
**Serial No. :** 09/942,146  
**Patent No. :** N/A  
**Title:** HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN O AS A NEW DRUG TARGET AND SUBUNIT VACCINE CANDIDATE  
**Date:** 9/4/2003  
**Our File:** 960296.98342  
**Attorney:** ZREN  
**Secretary:** arolph

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: 9/4/03

  
Attorney of Record



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Teresa Compton, et al.  
Serial No.: 09/942,146  
Filed: August 29, 2001  
For: HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN O AS A  
NEW DRUG TARGET AND SUBUNIT VACCINE  
CANDIDATE  
Group Art Unit: 1645  
Examiner: --

---

### RESPONSE TO NOTICE TO COMPLY

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the August 25, 2003 Notice to Comply, please amend the  
above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 3 of this paper.

**Amendments to the Specification:**

Please insert the enclosed paper copy of the sequence listing into the application after the section titled "Abstract of the Disclosure."

REMARKS

In the Notice to Comply, the applicants are invited to provide a paper copy and a computer readable form of the sequence listing. In response, the applicants submitted these items herewith. A statement under 37 C.F.R. 1.821 (f) and (g) is also enclosed.

No fees are believed necessary to enter this response. However, if any fees are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Teresa Compton, et al.

September 4, 2003

By: 

Zhibin Ren  
QUARLES & BRADY LLP  
411 East Wisconsin Avenue  
Milwaukee, WI 53202  
Reg. No.: 47,897  
(414) 277-5633

QBMKE\960296.98342\5463774.1



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/942,146	06/26/2002	Teresa Compton	960296.98342

27114  
QUARLES & BRADY LLP  
411 E. WISCONSIN AVENUE, SUITE 2040  
MILWAUKEE, WI 53202-4497

CONFIRMATION NO. 6687

FORMALITIES LETTER



\*OC000000010748733\*

Date Mailed: 08/25/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

AUG 27 2003



SEQUENCE LISTING

<110> Compton, Teresa  
Huber, Mary T.

<120> Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate

<130> 960296.98342

<140> 09/942,146  
<141> 2001-08-29

<150> 09/627,986  
<151> 2000-07-28

<150> 60/146,180  
<151> 1999-07-29

<160> 1

<170> PatentIn version 3.2.

<210> 1  
<211> 465  
<212> PRT  
<213> Human cytomegalovirus

<400> 1

Met Gly Arg Lys Glu Met Met Val Arg Asp Val Pro Lys Met Phe Val  
1 5 10 15

Leu Ile Ser Ile Ser Phe Leu Leu Val Ser Phe Ile Asn Cys Lys Val  
20 25 30

Met Ser Lys Ala Leu Tyr Asn Arg Pro Trp Arg Gly Leu Val Leu Ser  
35 40 45

Lys Ile Gly Lys Tyr Lys Leu Asp Gln Leu Lys Leu Glu Ile Leu Arg  
50 55 60

Gln Leu Glu Thr Thr Ile Ser Thr Lys Tyr Asn Val Ser Lys Gln Pro  
65 70 75 80

Val Lys Asn Leu Thr Met Asn Thr Glu Phe Pro Gln Tyr Tyr Ile Leu  
85 90 95

Ala Gly Pro Ile Gln Asn Tyr Ser Ile Thr Tyr Leu Trp Phe Asp Phe  
100 105 110

Tyr Ser Thr Gln Leu Arg Lys Pro Ala Lys Tyr Val Tyr Ser Gln Tyr  
115 120 125

Asn His Thr Ala Lys Thr Ile Thr Phe Arg Pro Pro Pro Cys Gly Arg  
130 135 140

Val Pro Ser Met Thr Cys Leu Ser Glu Met Leu Asn Val Ser Lys Arg  
145 150 155 160

Asn Asp Thr Gly Glu Gln Gly Cys Gly Asn Phe Thr Thr Phe Asn Pro  
165 170 175

Met Phe Phe Asn Val Pro Arg Trp Asn Thr Lys Leu Tyr Val Gly Pro  
180 185 190

Thr Lys Val Asn Val Asp Ser Gln Thr Ile Tyr Phe Leu Gly Leu Thr  
195 200 205

Ala Leu Leu Leu Arg Tyr Ala Gln Arg Asn Cys Thr His Ser Phe Tyr  
210 215 220

Leu Val Asn Ala Met Ser Arg Asn Leu Phe Arg Val Pro Lys Tyr Ile  
225 230 235 240

Asn Gly Thr Lys Leu Lys Asn Thr Met Arg Lys Leu Lys Arg Lys Gln  
245 250 255

Ala Pro Val Lys Glu Gln Phe Glu Lys Lys Ala Lys Lys Thr Gln Ser  
260 265 270

Thr Thr Thr Pro Tyr Phe Ser Tyr Thr Thr Ser Ala Ala Leu Asn Val  
275 280 285

Thr Thr Asn Val Thr Tyr Ser Ile Thr Thr Ala Ala Arg Arg Val Ser  
290 295 300

Thr Ser Thr Ile Ala Tyr Arg Pro Asp Ser Ser Phe Met Lys Ser Ile  
305 310 315 320

Met Ala Thr Gln Leu Arg Asp Leu Ala Thr Trp Val Tyr Thr Thr Leu  
325 330 335

Arg Tyr Arg Gln Asn Pro Phe Cys Glu Pro Ser Arg Asn Arg Thr Ala  
340 345 350

Val Ser Glu Phe Met Lys Asn Thr His Val Leu Ile Arg Asn Glu Thr  
355 360 365

Pro Tyr Thr Ile Tyr Gly Thr Leu Asp Met Ser Ser Leu Tyr Tyr Asn  
370 375 380

Glu Thr Met Phe Val Glu Asn Lys Thr Ala Ser Asp Ser Asn Lys Thr  
385 390 395 400

Thr Pro Thr Ser Pro Ser Met Gly Phe Gln Arg Thr Phe Ile Asp Pro  
405 410 415

Leu Trp Asp Tyr Leu Asp Ser Leu Leu Phe Leu Asp Glu Ile Arg Asn  
420 425 430

Phe Ser Leu Arg Ser Pro Thr Tyr Val Asn Leu Thr Pro Pro Glu His  
435 440 445

Arg Arg Ala Val Asn Leu Ser Thr Ser Asn Ser Leu Trp Trp Trp Leu  
450 455 460

Gln  
465

NOV 23 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: September 4, 2003

  
Zhibin Ren, Reg. No. 47,897

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Teresa Compton, et al.  
Serial No.: 09/942,146  
Filed: August 29, 2001  
For: HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN O AS A NEW  
DRUG TARGET AND SUBUNIT VACCINE  
Group Art Unit: 1645  
Examiner: --  
Ref. No.: 960296.98342

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)**

Dear Sir:

The undersigned, an attorney registered to practice before the U.S. Patent and Trademark Office (USPTO) and representing the applicants in the above-identified patent application does hereby state and affirm that the content of the enclosed diskette and the content of the enclosed paper copy of the sequence listing are believed to be the same. No new matter has been added.

Respectfully submitted,

Teresa Compton, et al.

September 4, 2003

By:   
Zhibin Ren  
Reg. No. 47,897  
QUARLES & BRADY LLP  
411 East Wisconsin Avenue  
Milwaukee, WI 53202-4497  
TEL (414) 277-5633  
FAX (414) 271-3552



**SEQUENCE LISTING**

Applicant(s): Teresa Compton, et al.

Serial No.: 09/942,146

Filed: August 29, 2001

For: HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN O  
AS A NEW DRUG TARGET AND SUBUNIT VACCINE  
CANDIDATE

Group Art Unit: 1645

Attorney Docket: 960296.98342 (ZREN)

Recordation Date: September 4, 2003

**BEST AVAILABLE COPY**